Legal & General Group Plc increased its position in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 1.3% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 61,371 shares of the specialty pharmaceutical company’s stock after buying an additional 770 shares during the period. Legal & General Group Plc’s holdings in AMAG Pharmaceuticals were worth $1,384,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of the company. Advisors Asset Management Inc. boosted its stake in AMAG Pharmaceuticals by 259.9% in the first quarter. Advisors Asset Management Inc. now owns 6,931 shares of the specialty pharmaceutical company’s stock worth $156,000 after buying an additional 5,005 shares in the last quarter. Mason Street Advisors LLC boosted its stake in AMAG Pharmaceuticals by 7.4% in the first quarter. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock worth $181,000 after buying an additional 554 shares in the last quarter. Sei Investments Co. boosted its stake in AMAG Pharmaceuticals by 0.7% in the first quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock worth $188,000 after buying an additional 54 shares in the last quarter. Baird Financial Group Inc. purchased a new position in shares of AMAG Pharmaceuticals during the first quarter worth approximately $220,000. Finally, Affinity Investment Advisors LLC raised its position in shares of AMAG Pharmaceuticals by 51.4% in the first quarter. Affinity Investment Advisors LLC now owns 9,747 shares of the specialty pharmaceutical company’s stock worth $220,000 after buying an additional 3,310 shares during the last quarter.
AMAG Pharmaceuticals, Inc. (AMAG) traded up 1.18% during mid-day trading on Friday, hitting $17.15. The company’s stock had a trading volume of 790,931 shares. The firm has a 50 day moving average of $18.88 and a 200-day moving average of $20.58. AMAG Pharmaceuticals, Inc. has a 52-week low of $16.00 and a 52-week high of $36.83. The firm’s market cap is $605.19 million.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The business had revenue of $158.39 million during the quarter, compared to analysts’ expectations of $158.83 million. During the same period last year, the company posted $1.45 EPS. The business’s revenue was up 24.3% on a year-over-year basis. On average, equities research analysts expect that AMAG Pharmaceuticals, Inc. will post ($1.37) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was reported by BNB Daily and is owned by of BNB Daily. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/legal-general-group-plc-boosts-position-in-amag-pharmaceuticals-inc-amag-updated-updated-updated.html.
A number of research analysts have commented on the company. Cantor Fitzgerald reiterated a “hold” rating and issued a $23.00 price objective on shares of AMAG Pharmaceuticals in a research report on Tuesday, May 2nd. Jefferies Group LLC reiterated a “buy” rating and issued a $34.00 price objective (down from $40.00) on shares of AMAG Pharmaceuticals in a research report on Wednesday, May 3rd. ValuEngine upgraded AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, July 25th. Barclays PLC restated a “hold” rating and issued a $25.00 price target on shares of AMAG Pharmaceuticals in a research report on Friday, May 5th. Finally, Zacks Investment Research lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 26th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $28.09.
In other AMAG Pharmaceuticals news, SVP Julie Krop sold 4,938 shares of AMAG Pharmaceuticals stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $20.00, for a total value of $98,760.00. Following the completion of the transaction, the senior vice president now directly owns 28,336 shares of the company’s stock, valued at approximately $566,720. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 3.80% of the company’s stock.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.